The price tag on the FDA’s aggressive regulatory push
TL;DR
An opinion piece argues that FDA leaders Peter Marks and Vinay Prasad have pursued a rigorous, aggressive regulatory approach that comes with costs for biotech firms and patients, fueling debate over approving drugs with uncertain benefits.
Topics:businesshealth-policy#biotech-policy#drug-approvals#fda#health-policy#peter-marks#vinay-prasad
- The extremism of the FDA’s Marks and Prasad has come with costs statnews.com
- F.D.A. Faces Upset Over Denials of New Drugs - The New York Times The New York Times
- FDA reversals leave investors worrying about the fates of other experimental drugs CNBC
- MAHA Is Bringing Chaos to Biotech Investment Beyond Just Vaccines WSJ
- Accusations Fly as Pharmaceutical Executives Challenge the FDA Bloomberg.com
Want the full story? Read the original reporting
Read on statnews.com